uniQure NV
Închisă
49.16 11.52
Rezumat
Modificarea prețului
24h
Minim
44.17
Maxim
49.51
Venit | -16M -54M |
|---|---|
Vânzări | -2M 3.6M |
EPS | -0.73 |
Marjă de profit | -1,502.948 |
Angajați | 221 |
EBITDA | 13M -36M |
Recomandări | Puternic Cumpărare |
|---|---|
Prognoză pe 12 luni | +33.66% upside |
Următoarele câștiguri | 28 iul. 2026 |
|---|
Capitalizare de piață | 454M 1.8B |
|---|---|
Deschiderea anterioară | 37.64 |
Închiderea anterioară | 49.16 |
uniQure NV Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Despre uniQure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
